Devazepide
Product Name :
Devazepide
Description:
Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC50s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders.
CAS:
103420-77-5
Molecular Weight:
408.45
Formula:
C25H20N4O2
Chemical Name:
N-[(3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-1H-indole-2-carboxamide
Smiles :
CN1C2=CC=CC=C2C(=N[C@H](NC(=O)C2=CC3=CC=CC=C3N2)C1=O)C1C=CC=CC=1
InChiKey:
NFHRQQKPEBFUJK-HSZRJFAPSA-N
InChi :
InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC50s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders.{{Cetirizine} site|{Cetirizine} Histamine Receptor|{Cetirizine} Purity & Documentation|{Cetirizine} In Vivo|{Cetirizine} manufacturer|{Cetirizine} Epigenetics} |Product information|CAS Number: 103420-77-5|Molecular Weight: 408.{{Troglitazone} web|{Troglitazone} Autophagy|{Troglitazone} Technical Information|{Troglitazone} Formula|{Troglitazone} manufacturer|{Troglitazone} Cancer} 45|Formula: C25H20N4O2|Chemical Name: N-[(3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-1H-indole-2-carboxamide|Smiles: CN1C2=CC=CC=C2C(=N[C@H](NC(=O)C2=CC3=CC=CC=C3N2)C1=O)C1C=CC=CC=1|InChiKey: NFHRQQKPEBFUJK-HSZRJFAPSA-N|InChi: InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 200 mg/mL (489.PMID:23543429 66 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|Devazepide (oral gavage; 4 mg/kg; twice per day) significantly accelerates cholesterol crystallization and crystal growth to microlithiasis, and the formation of gallstones in mice. Devazepide (intraperitoneal injection; 0.1-1 mg/kg) has opposite effects on spontaneous locomotor activity, and on caerulein- and apomorphine-induced hypomotility in the mouse.|Products are for research use only. Not for human use.|